Today on TheBrief
Fast, reliable briefs on the latest medical research. Each one gives you the finding, the population it applies to, what it changes in practice, and a link straight to the original source.
Neurology
The FDA-labeled population for FAYUVI is pediatric patients with MPS IIIA and preserved neurodevelopmental function, making timely developmental assessment central to treatment selection.
Rayan Salih · October 29, 2026 · 6 min
Oncology
Accelerated approval adds dostarlimab as an initial option for selected patients with untreated stage II or III MSI-H or dMMR rectal cancer, making organ preservation an early multidisciplinary decision.
Rayan Salih · 6 min read
Clinical Briefs
Traditional approval retains a narrow, tissue-agnostic indication for adults and children with previously treated, unresectable or metastatic TMB-high solid tumors and no satisfactory alternatives.
Rayan Salih · 6 min read
Oncology
The FDA has moved pirtobrutinib into previously untreated CLL and SLL, expanding first-line choice when therapy is indicated rather than reserving the drug for later lines.
Rayan Salih · 6 min read
Oncology
Accelerated approval makes dostarlimab an initial option for previously untreated stage II or III MSI-H/dMMR rectal cancer, with the possibility of avoiding chemotherapy, radiation and surgery.
Rayan Salih · 6 min read
Heart and vascular medicine
Trial results, device approvals and practice guidance across cardiology, interventional care and vascular medicine.
Cancer care and research
Practice-changing oncology and hematology research, from early detection through survivorship.
Brain, nerve and cognitive care
Neurology and neuroscience briefs covering diagnosis, disease-modifying therapy and long-term management.
Diabetes, obesity and hormone health
Metabolic medicine: glycemic management, GLP-1 therapeutics, thyroid disease and endocrine practice.
OBGYN and women's medicine
Obstetric, gynecologic and women's health evidence across the reproductive lifespan.
Psychiatry and behavioral medicine
Psychiatry, behavioral health and sleep medicine research with an eye on what changes in clinic.
Infection, immunity and prevention
Infectious disease, immunology and infection prevention, from outbreak response to vaccine evidence.
Regulation, coverage and access
Policy, payment and public health decisions that shape how clinicians practice and patients get care.
Technology at the bedside
Medical devices, diagnostics, digital health and AI tools moving from pipeline into practice.
Reporting from the meetings
Late-breaking data and session highlights from the major medical congresses.
Across the specialties
Concise evidence briefs from across internal medicine, surgery, pediatrics and primary care.
Oncology
FDA traditional approval defines TMB-high solid tumors as at least 13 mutations per megabase. Eligibility depends on confirming that the reported result meets the new cutoff.
Rayan Salih · 7 min read
Oncology
The FDA approved lirafugratinib for previously treated cholangiocarcinoma with an FGFR2 fusion or other rearrangement, adding a biomarker-defined option after earlier therapy.
Dr. Abu Bakar · 6 min read
Women's Health
The FDA approved imlunestrant plus abemaciclib for adults with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after endocrine progression. ESR1 testing now determines eligibility.
Dr. Abu Bakar · 6 min read
Innovation & Devices
Updated Amplatzer Amulet instructions sort pulmonary artery injury risk into three distance bands for patients undergoing left atrial appendage closure.
Dr. Abu Bakar · 6 min read
Oncology
In a phase 3 head-to-head trial, [177Lu]Lu-edotreotide extended progression-free survival compared with everolimus in progressive, somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Rayan Salih · 6 min read
Women's Health
The FDA approval applies to adults with ER-positive, HER2-negative advanced or metastatic breast cancer harboring an ESR1 mutation after endocrine-therapy progression. Guardant360 CDx is the companion diagnostic.
Rayan Salih · 7 min read
Oncology
The FDA’s accelerated approval covers previously treated adults with advanced nonsquamous NSCLC harboring activating HER2 tyrosine-kinase-domain mutations detected by an approved test.
Rayan Salih · 6 min read
Oncology
The FDA expanded Anktiva plus BCG to adults with BCG-unresponsive, high-grade papillary-only non–muscle-invasive bladder cancer, adding a bladder-preserving option for this underserved group.
Dr. Abu Bakar · 7 min read
One story a day
One health journey each morning — no advice, no alarm, just company for the road.
Health Policy
An FDA Class I recall covers specified CooperSurgical INCA infant nasal CPAP set lots because tubing-to-cannula connections may loosen and interrupt respiratory support.
Dr. Abu Bakar · 6 min read
Infectious Disease
The Class I recall applies to Medline convenience kits containing affected BD ChloraPrep applicators. Facilities should quarantine listed inventory and assess patients with credible exposure and compatible illness.
Dr. Abu Bakar · 6 min read
Oncology
FDA accelerated approval covers selected previously untreated adults with MSI-H or dMMR locally advanced rectal cancer, allowing standard chemoradiation and surgery to be deferred when a complete clinical response is sustained.
Rayan Salih · 7 min read
Clinical Briefs
A Class I recall covers convenience kits containing potentially nonsterile 0.9% sodium chloride flush ampules. Affected ampules should be removed and discarded to prevent intravenous exposure.
Rayan Salih · 6 min read
Oncology
The FDA approval applies to adults with untreated stage II or III locally advanced rectal cancer whose tumors are MSI-H or dMMR. Testing must occur before the initial treatment strategy is fixed.
Rayan Salih · 6 min read
Endocrinology & Metabolism
The FDA boxed warning makes hypophosphatemia a central consideration when ferric carboxymaltose is selected, particularly for patients with risk factors or repeated exposure.
Dr. Abu Bakar · 6 min read
Amanda Gray
Contributing writer · PA
A board-certified Physician Assistant who has been practicing medicine since 2008. My clinical experience includes occupational medicine, urgent care, family medicine, and cardiology, with the majority of my career…
Egbavwe Pela
Contributing writer
Dr. Abu Bakar
Contributing writer · PharmD, PhD (Pharmacology)
A Pharm-D and PhD in Pharmacology from Punjab University College of Pharmacy, and I have worked as a registered hospital pharmacist at Jinnah Hospital Lahore. Over the past six years in clinical practice, I have seen…
Rayan Salih
Contributing writer · PharmD, RPh
Rayan is a pharmacist, life science communicator, and health policy researcher with a deep interest in ensuring patient access to innovative and life-changing therapies. She obtained her PharmD at Rosalind Franklin…